PL1776142T4 - Przeciwciała antagonistyczne wobec IL-17 - Google Patents

Przeciwciała antagonistyczne wobec IL-17

Info

Publication number
PL1776142T4
PL1776142T4 PL05770286T PL05770286T PL1776142T4 PL 1776142 T4 PL1776142 T4 PL 1776142T4 PL 05770286 T PL05770286 T PL 05770286T PL 05770286 T PL05770286 T PL 05770286T PL 1776142 T4 PL1776142 T4 PL 1776142T4
Authority
PL
Poland
Prior art keywords
antagonistic antibodies
antagonistic
antibodies
Prior art date
Application number
PL05770286T
Other languages
English (en)
Polish (pl)
Other versions
PL1776142T6 (pl
PL1776142T3 (pl
Inventor
Franco E. Di Padova
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Wim Van Den Berg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1776142(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1776142T3 publication Critical patent/PL1776142T3/pl
Publication of PL1776142T6 publication Critical patent/PL1776142T6/pl
Publication of PL1776142T4 publication Critical patent/PL1776142T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05770286T 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17 PL1776142T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP05770286.2A EP1776142B9 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (3)

Publication Number Publication Date
PL1776142T3 PL1776142T3 (pl) 2011-12-30
PL1776142T6 PL1776142T6 (pl) 2016-06-30
PL1776142T4 true PL1776142T4 (pl) 2018-04-30

Family

ID=32982602

Family Applications (4)

Application Number Title Priority Date Filing Date
PL05770286T PL1776142T4 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL10174725T PL2366405T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL10174725T PL2366405T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17

Country Status (40)

Country Link
US (9) US7807155B2 (enEXAMPLES)
EP (5) EP2366405B1 (enEXAMPLES)
JP (1) JP4682200B2 (enEXAMPLES)
KR (2) KR20080029018A (enEXAMPLES)
CN (1) CN101001645B (enEXAMPLES)
AR (1) AR050200A1 (enEXAMPLES)
AT (1) ATE517924T1 (enEXAMPLES)
AU (2) AU2005268857C1 (enEXAMPLES)
BE (1) BE2015C041I2 (enEXAMPLES)
BR (3) BR122017009404B1 (enEXAMPLES)
CA (1) CA2573586C (enEXAMPLES)
CY (6) CY1111963T1 (enEXAMPLES)
DK (4) DK2366405T3 (enEXAMPLES)
EC (1) ECSP077198A (enEXAMPLES)
ES (4) ES2677245T3 (enEXAMPLES)
FR (1) FR15C0048I2 (enEXAMPLES)
GB (1) GB0417487D0 (enEXAMPLES)
HK (1) HK1256639A1 (enEXAMPLES)
HR (3) HRP20110758T4 (enEXAMPLES)
HU (4) HUE025815T2 (enEXAMPLES)
IL (1) IL180717A (enEXAMPLES)
LT (3) LT2902039T (enEXAMPLES)
LU (2) LU92768I2 (enEXAMPLES)
MA (1) MA28982B1 (enEXAMPLES)
MX (1) MX2007001338A (enEXAMPLES)
MY (1) MY144925A (enEXAMPLES)
NL (1) NL300749I2 (enEXAMPLES)
NO (9) NO336279B1 (enEXAMPLES)
NZ (1) NZ552658A (enEXAMPLES)
PE (1) PE20060418A1 (enEXAMPLES)
PL (4) PL1776142T4 (enEXAMPLES)
PT (4) PT2366405E (enEXAMPLES)
RU (2) RU2426741C3 (enEXAMPLES)
SG (1) SG155186A1 (enEXAMPLES)
SI (4) SI2902039T1 (enEXAMPLES)
TN (1) TNSN07034A1 (enEXAMPLES)
TR (1) TR201808057T4 (enEXAMPLES)
TW (1) TWI359153B (enEXAMPLES)
WO (1) WO2006013107A1 (enEXAMPLES)
ZA (1) ZA200700242B (enEXAMPLES)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
SI2913343T1 (sl) 2005-12-20 2019-01-31 Sbi Biotech Co., Ltd. Protitelo anti-ILT7
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
KR20080099290A (ko) 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
EP2046835B1 (en) 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
CA2687499C (en) 2007-05-29 2017-11-28 Novartis Ag New indications for anti-il-1-beta therapy
CA2690568A1 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2242504B1 (en) * 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR20160117643A (ko) * 2008-04-29 2016-10-10 암젠 리서치 (뮌헨) 게엠베하 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
MX2010012090A (es) 2008-05-05 2011-04-11 Novimmune Sa Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos.
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
PE20121094A1 (es) 2009-03-05 2012-09-13 Abbvie Inc Proteinas de union a il-17
ES2655877T3 (es) * 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
CN104974250A (zh) 2009-05-05 2015-10-14 诺维莫尼公司 抗il-17f抗体及其使用方法
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2777222A1 (en) * 2009-10-10 2011-04-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
FI4108671T3 (fi) 2010-10-01 2024-12-27 Modernatx Inc Muokattuja nukleosideja, nukleotideja ja nukleiinihappoja sekä niiden käyttötapoja
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
LT3111954T (lt) * 2010-11-05 2019-07-10 Novartis Ag Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
HRP20171034T1 (hr) 2011-01-14 2017-10-06 Ucb Biopharma Sprl Antitijelo koje veže il-17a i il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
AU2012236486B2 (en) * 2011-03-29 2016-06-23 Glaxosmithkline Llc Buffer system for protein purification
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20150064193A1 (en) * 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｔｗｅａｋ及びヒトｉｌ１７に対する二重特異性抗体並びにその使用
MX2014012640A (es) 2012-04-20 2015-01-15 Novartis Ag Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17.
UY34815A (es) 2012-05-22 2013-11-29 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos biespecíficos y sus métodos de uso
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
TW202014439A (zh) 2012-11-01 2020-04-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
KR101877109B1 (ko) 2013-02-08 2018-07-10 노파르티스 아게 항-il-17a 항체 및 자가면역 및 염증성 장애의 치료에서의 그의 용도
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015070697A1 (zh) * 2013-11-18 2015-05-21 上海恒瑞医药有限公司 Il-17a结合物及其用途
JP2017508446A (ja) * 2014-01-28 2017-03-30 北京韓美薬品有限公司 二機能性融合タンパク質及びその製造方法並びに使用
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
AU2015313827C1 (en) * 2014-09-10 2018-08-30 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AU2016208161B2 (en) 2015-01-12 2020-01-16 Affibody Ab IL-17A-binding polypeptides
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA201792527A1 (ru) 2015-07-16 2018-06-29 Эли Лилли Энд Компани Лечение зуда
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
AU2016342578A1 (en) 2015-10-19 2018-03-29 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
KR102802736B1 (ko) 2016-03-10 2025-05-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
SI3426680T1 (sl) 2016-03-10 2025-07-31 Acceleron Pharma Inc. Vezavni proteini receptorja aktivina tipa 2 in njihove uporabe
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
CN109476733A (zh) 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法
EP3514176B1 (en) 2016-09-14 2021-12-15 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to il-17a and functional fragment thereof
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN111344043A (zh) 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
EP3773717A4 (en) * 2018-03-29 2022-05-11 REMD Biotherapeutics, Inc. TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
CN112513078B (zh) 2018-07-31 2022-11-18 沈为群 抗il-17a抗体及其用途
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
KR20210122243A (ko) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
NZ778977A (en) 2019-02-18 2025-06-27 Lilly Co Eli Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CA3142267A1 (en) 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
EP4036113A4 (en) 2019-07-26 2023-01-18 Sinocelltech Ltd. HUMANIZED ANTI-IL17A ANTIBODIES AND THEIR USE
WO2021018191A1 (zh) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
TWI870471B (zh) * 2019-09-25 2025-01-21 國立大學法人東京大學 全身性硬化症治療用醫藥組合物
EP4042167B1 (en) 2019-09-30 2025-04-09 Janssen Pharmaceutica NV Compositions and methods for an il-17 target engagement assay with large molecule modulators
WO2021099924A1 (en) 2019-11-19 2021-05-27 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
KR20220110512A (ko) 2019-12-06 2022-08-08 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
AU2021296436A1 (en) 2020-06-23 2023-02-02 Novartis Ag Methods of treating Thyroid Eye Disease and Graves' Orbitopahy using Interleukin-17 (IL-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
CN116635416A (zh) 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
CN119137115A (zh) 2022-04-25 2024-12-13 诺华股份有限公司 Il-17抑制剂的晶型
US20250313618A1 (en) 2022-05-16 2025-10-09 Novartis Ag Methods of treating giant cell arteritis using Interleukin-17 (IL-17) Antagonists
EP4525914A1 (en) 2022-05-18 2025-03-26 Novartis AG Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4406553A1 (en) * 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) * 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
PT839196E (pt) * 1995-07-19 2005-09-30 Inst Genetics Llc Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
ATE222768T1 (de) 1995-10-27 2002-09-15 Schering Corp Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
EP0959897B1 (en) 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
DE69833876T2 (de) 1997-11-10 2007-05-24 Cytimmune Sciences, Inc. Zusammensetzungen und verfahren für die gezielte abgabe von faktoren
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU2004799A (en) 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU2315099A (en) 1998-01-09 1999-07-26 Immunex Corporation Il-17rh dna and polypeptides
EP1053343A2 (en) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting of genetic vaccine vectors
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
IL141869A0 (en) 1998-09-17 2002-03-10 Zymogenetics Inc Mammalian transforming growth factor beta-9 (ztgfss9)
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
JP2002534122A (ja) 1999-01-11 2002-10-15 シェーリング コーポレイション インターロイキン−１７関連哺乳動物サイトカイン、それをコードするポリヌクレオチド、使用
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
JP4841727B2 (ja) 1999-02-12 2011-12-21 ザ スクリプス リサーチ インスティチュート 抗血管新生治療及び免疫治療の組み合わせを用いる腫瘍及び転移の治療方法
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP2281843B1 (en) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
WO2002033083A2 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
AU2002246746B2 (en) 2000-10-18 2007-05-31 Kirin-Amgen, Inc. Methods for treating rheumatoid arthritis using il-17 antagonists
ES2360481T3 (es) 2001-01-25 2011-06-06 Zymogenetics, Inc. Procedimiento para tratar psoriasis usando un antagonista de il- 17d.
PT1391464E (pt) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
WO2005023177A2 (en) * 2003-05-21 2005-03-17 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
CA2573586A1 (en) 2006-02-09
AU2010201689B2 (en) 2011-09-29
EP2902039B1 (en) 2018-04-11
LT2902039T (lt) 2018-06-25
DK1776142T6 (en) 2015-07-06
PT1776142E (pt) 2011-10-06
HUE025815T2 (en) 2016-04-28
RU2426741C3 (ru) 2017-11-15
NO2018007I1 (no) 2018-02-14
NO2015023I1 (no) 2015-11-02
DK2366405T3 (en) 2015-05-11
PL1776142T6 (pl) 2016-06-30
HRP20110758T4 (hr) 2015-07-31
LTPA2018515I1 (lt) 2018-10-25
CY1116256T1 (el) 2017-02-08
MX2007001338A (es) 2008-03-11
PL1776142T3 (pl) 2011-12-30
JP4682200B2 (ja) 2011-05-11
HK1101277A1 (en) 2007-10-12
NO337129B1 (no) 2016-01-25
NO2016017I1 (no) 2016-08-23
US20230235038A1 (en) 2023-07-27
HUE038187T2 (hu) 2018-10-29
NO337286B1 (no) 2016-02-29
HUS1500037I1 (hu) 2017-10-30
NO20150064L (no) 2007-03-30
US20170355762A1 (en) 2017-12-14
PL2902039T3 (pl) 2018-09-28
LTC1776142I2 (lt) 2022-07-11
NO20151787L (no) 2006-02-06
PL2364729T6 (pl) 2016-06-30
TWI359153B (en) 2012-03-01
BR122018075556B1 (pt) 2022-10-18
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
EP2366405A3 (en) 2012-01-18
US20150152178A1 (en) 2015-06-04
NZ552658A (en) 2009-11-27
NO2015023I2 (no) 2015-10-26
NO20150065L (no) 2007-03-30
NO341384B1 (no) 2017-10-30
EP3409288A1 (en) 2018-12-05
BE2015C041I2 (enEXAMPLES) 2024-10-08
PL2366405T3 (pl) 2015-08-31
ES2367440T7 (es) 2015-07-14
EP2364729B1 (en) 2014-05-14
EP1776142B3 (en) 2015-06-24
MA28982B1 (fr) 2007-11-01
DK2364729T6 (en) 2015-07-06
HK1207559A1 (en) 2016-02-05
US20120107325A1 (en) 2012-05-03
ATE517924T1 (de) 2011-08-15
KR20070036166A (ko) 2007-04-02
PT2902039T (pt) 2018-07-17
DK2364729T3 (da) 2014-07-21
NL300749I2 (nl) 2017-11-02
ES2487533T7 (es) 2015-07-14
EP1776142B1 (en) 2011-07-27
PL2364729T3 (pl) 2014-10-31
EP2366405A2 (en) 2011-09-21
PT2366405E (pt) 2015-06-30
SI2364729T1 (sl) 2014-08-29
ECSP077198A (es) 2007-02-28
MY144925A (en) 2011-11-30
SI1776142T1 (sl) 2011-11-30
RU2011113153A (ru) 2012-10-20
LU92768I2 (fr) 2015-11-03
CN101001645A (zh) 2007-07-18
LTPA2015029I1 (lt) 2022-07-11
PE20060418A1 (es) 2006-06-15
NO348010B1 (no) 2024-06-17
SG155186A1 (en) 2009-09-30
FR15C0048I1 (fr) 2015-08-28
EP2366405B1 (en) 2015-02-25
BR122017009404B1 (pt) 2022-02-22
EP1776142B9 (en) 2016-09-07
AU2005268857A1 (en) 2006-02-09
US10344084B2 (en) 2019-07-09
JP2008507988A (ja) 2008-03-21
BRPI0513078C1 (pt) 2021-05-25
NO336279B1 (no) 2015-07-06
US7807155B2 (en) 2010-10-05
TR201808057T4 (tr) 2018-06-21
EP2364729B3 (en) 2015-06-24
IL180717A0 (en) 2007-06-03
BRPI0513078A (pt) 2008-04-22
BRPI0513078B8 (pt) 2019-08-27
AU2005268857B2 (en) 2010-01-28
US20250122277A1 (en) 2025-04-17
SI2366405T1 (sl) 2015-07-31
CY2018027I1 (el) 2020-05-29
KR20080029018A (ko) 2008-04-02
HUS1800040I1 (hu) 2018-11-28
US20190270804A1 (en) 2019-09-05
ES2367440T3 (es) 2011-11-03
US8617552B2 (en) 2013-12-31
KR100852523B1 (ko) 2008-08-14
US20100215666A1 (en) 2010-08-26
CY1111963T1 (el) 2015-11-04
NO20070985L (no) 2007-03-30
CA2573586C (en) 2013-06-25
SI2902039T1 (en) 2018-07-31
CY2015030I1 (el) 2015-11-04
HK1256639A1 (en) 2019-09-27
CY1120723T1 (el) 2019-12-11
AU2005268857C1 (en) 2012-01-19
EP2902039A1 (en) 2015-08-05
WO2006013107A1 (en) 2006-02-09
EP1776142A1 (en) 2007-04-25
PT2364729E (pt) 2014-09-01
ES2367440T9 (es) 2021-04-28
CY2018027I2 (el) 2020-05-29
NO20171697A1 (no) 2007-03-30
KR100852523B9 (ko) 2025-03-28
CY2015030I2 (el) 2017-11-14
TW200617025A (en) 2006-06-01
RU2426741C2 (ru) 2011-08-20
BRPI0513078B1 (pt) 2019-02-19
CN101001645B (zh) 2012-09-05
FR15C0048I2 (fr) 2015-11-20
DK1776142T3 (da) 2011-10-31
HRP20181069T1 (hr) 2018-09-07
TNSN07034A1 (en) 2008-06-02
US8119131B2 (en) 2012-02-21
HRP20110758T1 (en) 2011-11-30
US9765140B2 (en) 2017-09-19
ES2487533T3 (es) 2014-08-21
AU2010201689A1 (en) 2010-05-20
US20140079719A1 (en) 2014-03-20
GB0417487D0 (en) 2004-09-08
ES2677245T3 (es) 2018-07-31
CY1115444T1 (el) 2017-01-04
AU2005268857B8 (en) 2010-05-27
ZA200700242B (en) 2008-08-27
EP2364729A2 (en) 2011-09-14
EP2364729A3 (en) 2012-01-18
HRP20150480T1 (hr) 2015-07-17
ES2536228T3 (es) 2015-05-21
DK2902039T3 (en) 2018-07-16
US20090280131A1 (en) 2009-11-12
LUC00088I2 (enEXAMPLES) 2018-12-17
AR050200A1 (es) 2006-10-04
IL180717A (en) 2012-07-31

Similar Documents

Publication Publication Date Title
HUS1800040I1 (hu) IL-17 antagonista antitestek
IL181575A0 (en) Anti-ox40l antibodies
IL237756A0 (en) Antibody compositions
IL228033A0 (en) Antibodies
IL179672A0 (en) Anti-cd3 antibodies
IL216381A0 (en) Antagonistic human light-specific human monoclonal antibodies
IL182554A0 (en) Anti-addl antibodies and uses thereof
GB0420466D0 (en) Anti-glucan antibodies
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
ZA200701952B (en) Anti-OX40L antibodies
GB0413257D0 (en) Backpack
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0402642D0 (en) Antibodies
GB0402641D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0413446D0 (en) Spot-on